The levels of IAPPO-IgA (and IAPPO-IgM) were significantly higher in APOE4-non-carrying AD patients compared with controls whereas, in APOE4-carrying AD patients, the IAPPO-IgA levels were decreased. This evidence concerns the gene CD79A and Alzheimer disease.